"This approval signals a new era in the treatment of prostate cancer, representing a shift toward more targeted, early intervention," said Prostate Cancer Foundation Chief Executive Gina Carithers.

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated ...

President Joe Biden recently gave an update on his treatment for metastatic prostate cancer. A urologist explains ways to ...

A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a study conducted by researchers at Umeå University together with ...

Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered—chronological age. The study, published ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.